Replication of the Heads Up Atopic Dermatitis Trial With Registry Data

Recruiting now

Conditions studied: Atopic Dermatitis

In brief

The goal is the replication of the primary outcome (EASI 75 at week 16) of the Heads Up trial (Blauvelt, A, Teixeira, H, Simpson, E et al (2021) doi:10.1001/jamadermatol.2021.3023) and the evaluation of the patient reported outcomes (POEM, DLQI and RECAP) in a head-to-head comparison of upadacitinib versus dupilumab treatment in moderate-to-severe atopic dermatitis (AD).

Key facts

Study ID

NCT06937788

Run by

Technische Universität Dresden

People needed

240

Starts

2021-08-02

Expected to finish

2025-12-31

Last updated by the study team

2025-08-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Chronic AD with onset of symptoms at least 3 years prior to baseline
• Meets UK working party criteria
• EASI score ≥ 16
• ≥ 10% body surface area (BSA) of AD involvement at baseline ("therapy start") visit

You may not qualify if…

• contraindications according to upadacitinib or dupilumab labeling

Where it is running

• Center for Evidence Based Health Care — Dresden, Saxony, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.